The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go?

More than 25 years after the first peptide receptor radionuclide therapy (PRRT), the concept of somatostatin receptor (SSTR)-directed imaging and therapy for neuroendocrine tumors (NET) is seeing rapidly increasing use. To maximize the full potential of its theranostic promise, efforts in recent yea...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Theranostics
Main Authors: Werner, Rudolf A., Weich, Alexander, Kircher, Malte, Solnes, Lilja B., Javadi, Mehrbod S., Higuchi, Takahiro, Buck, Andreas K., Pomper, Martin G., Rowe, Steven P., Lapa, Constantin
Formato: Artigo
Idioma:Inglês
Publicado: Ivyspring International Publisher 2018
Assuntos:
Review
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6299695/
https://ncbi.nlm.nih.gov/pubmed/30613284
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.30357
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares